More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age These ...

-- Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment -- Made Significant Progress Strengthening the R&D Organization -- On Track to Exceed Net Cost Savings Targets ...

A month has gone by since the last earnings report for Pfizer (PFE). Shares have added about 3.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

The MarketWatch News Department was not involved in the creation of this content. -- Strengthened Commercial Execution Driving Topline Growth -- Continued Progress Across R&D Pipeline -- Expanded ...

The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The treatment ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and ...

Pfizer signed a deal with the White House to help Americans pay lower prices for prescription drugs. This agreement removes the uncertainty hanging over Pfizer's head related to the Trump ...

The treatment will be available by prescription to eligible patients this quarter, a Pfizer spokesperson told CNBC. It has a hefty $3.5 million price tag before insurance and other rebates, the ...